# Evaluation of the Safety and Efficacy of Abenacianine (VGT-309) to Identify Cancer in Subjects Undergoing Surgery for Cancer in the Lung

Source: https://onco.cc/trials/nct07499674/  
OnCo record `nct07499674` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Abenacianine in advanced solid tumours, run by Vergent Bioscience, Inc., now recruiting.

## Summary

Evaluation of the Safety and Efficacy of Abenacianine (VGT-309) to Identify Cancer in Subjects Undergoing Surgery for Cancer in the Lung is a phase 3 interventional study registered as NCT07499674 by Vergent Bioscience, Inc., with 132 participants planned, started 2026-03-31 and due to reach its primary completion in 2026-12. Interventions recorded: Abenacianine.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07499674
- Phase: 3
- Setting: A Phase 3, Multi-center, Randomized, Open Label Study to Evaluate the Safety and Efficacy of Abenacianine (VGT-309), a Tumor-Targeted, Activatable Fluorescent Imaging Agent, to Identify Cancer in Subjects Undergoing Surgery for Cancer in the Lung - VISUALIZE 2
- Sponsor: Vergent Bioscience, Inc.
- Enrolled: 132

## Sources

- ClinicalTrials.gov NCT07499674: https://clinicaltrials.gov/study/NCT07499674

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- companies: [Vergent Bioscience](https://onco.cc/companies/vergent-bioscience/)

---
JSON: https://onco.cc/api/v1/entities/nct07499674.json